A mid-size, top 5 European pharmaceutical company engaged PRA in a global Phase III study in 20 countries on patients with advanced breast cancer previously treated with or resistant to airmaximus an anthracycline and who are taxane resistant. By identifying optimal sites in in Russia, Ukraine, Belarus, and Estonia, PRA recruited 318 patients at 25 sites, compared to 450+ patients at 150 sites in Rest of World (ROW).
Explore related content and topics
Webinar
The Challenges of Patient Recruitment in Oncology Trials - Part 3
A Phase I through Phase III oncology trial costs approximately $56.3 million and lasts for eight years. In 2012, it was reported that a typical…
View Resource
Blog
Virtual Technology Strives to Make Better Research and Treatments for All
The use of virtual reality (VR) technology, wearable technology, and virtual clinical trials can provide researchers with a more convenient way to…
Read Story
Blog
Cancer Research and Clinical Development Since Last ASCO
Read Story
View all related content and resources for Oncology
Explore Insights